BAKER BROS. ADVISORS LP Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001263508

What is a 13F filing? Who files one and when · What 13F filings can't tell you

LargeFocusedHealth TiltHigh Turnover how tags are computed

Q4 2025 · 85 positions · Total reported value $16.29B · Top-10 concentration 76.6% · Updated 2026-10-18

Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR

Turnover: 24.2% · 8 new · 6 cut · 8 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q1 2026 → Q2 2026): +14.7% · vs SPY -0.1% · Prev Value $16.51B — last quarter positions weighted by this quarter price moves · ranking

In its Q4 2025 13F filing, BAKER BROS. ADVISORS LP disclosed 85 equity positions with a combined reported value of $16.29B. The filing implies a focused portfolio: its ten largest positions account for 76.6% of reported value. HoldingsHub classifies the profile as Large / Focused / Health Tilt / High Turnover.

The largest disclosed positions as of Q4 2025 were INCY ($3.04B), ONC ($2.67B), MDGL ($1.25B). By sector, the heaviest allocations are Health Care 99.0%, Other 1.0%.

Versus the prior quarter, BAKER BROS. ADVISORS LP opened 8 new positions, trimmed 6 and fully exited 8, a turnover rate of 24.2% of positions. The portfolio's overlap with the prior quarter was 78% of names.

The largest new positions opened in Q4 2025 were TERN ($38.38M), JBIO ($25.32M), BCRX ($22.02M).

Of the 8 positions fully exited versus the prior quarter, the largest were MRUS ($54.08M), NTLA ($47.44M), RNAM ($27.23M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q4 2025)

  • TERN TERNS PHARMACEUTICALS INC · $38.38M
  • JBIO JADE BIOSCIENCES INC · $25.32M
  • BCRX BIOCRYST PHARMACEUTICALS INC · $22.02M
  • CNTA CENTESSA PHARMACEUTICALS PLC · $16.78M
  • DYN DYNE THERAPEUTICS INC · $15.91M
  • ABSI ABSCI CORPORATION · $7.45M
  • RCUS ARCUS BIOSCIENCES INC · $6.43M
  • MPLT MAPLIGHT THERAPEUTICS INC · $6.41M

Fully Exited (vs previous quarter)

  • MRUS MERUS N V · prev qtr: $54.08M
  • NTLA INTELLIA THERAPEUTICS INC · prev qtr: $47.44M
  • RNAM AVIDITY BIOSCIENCES INC · prev qtr: $27.23M
  • PCVX Vaxcyte Inc · prev qtr: $23.08M
  • CDTX CIDARA THERAPEUTICS INC · prev qtr: $21.76M
  • AKRO AKERO THERAPEUTICS INC · prev qtr: $15.41M
  • ACLX ARCELLX INC · prev qtr: $13.70M
  • VKTX VIKING THERAPEUTICS INC · prev qtr: $9.62M

Insider Transactions (Form 4)

Latest BAKER BROS. ADVISORS LP buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

Transaction date Activity Security Shares Price Filing
2026-11-06 Buy MADRIGAL PHARMACEUTICALS, INC. 2,000 $396.61 SEC filing
2026-11-06 Buy MADRIGAL PHARMACEUTICALS, INC. 13,740 $388.29 SEC filing
2026-11-06 Buy MADRIGAL PHARMACEUTICALS, INC. 60,400 $383.01 SEC filing
2026-11-05 Buy Kodiak Sciences Inc. 81,729 $98.51 SEC filing
2026-11-05 Buy Kodiak Sciences Inc. 4,703 $98.51 SEC filing
2026-11-04 Buy Kodiak Sciences Inc. 151,916 $98.51 SEC filing
2026-11-04 Buy Kodiak Sciences Inc. 8,742 $98.51 SEC filing
2026-11-04 Buy MADRIGAL PHARMACEUTICALS, INC. 10,080 $368.11 SEC filing

All insider transactions →

Fund Profile

Baker BROS. Advisors is an SEC-registered 13F filer based in New York, NY, United States. As of Q2 2026 it reported 83 US equity positions with a combined value of $19.13B. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).

Firm Snapshot

  • Headquarters: NEW YORK, NY, United States
  • SEC registration: 801-73446 (status: Approved), registered 2012-03-05
  • Regulatory AUM (Form ADV): $28.15B as of 2026-03-27
  • Client mix (by RAUM): pension and profit-sharing plans 100%
  • Manages 2 private funds, of which 2 hedge funds

Portfolio Structure

  • 83 positions · $19.13B reported value (Q2 2026)
  • Top 10 holdings = 74.7% of reported value
  • Largest position: INCY (INCYTE CORP) at 18.2%
  • Average position size: $230.45M

Sector Tilt

  • Health Care 99.4%
  • (classified holdings cover 99% of value)

Quarterly Activity

  • Q2 2026: 8 new, 10 added, 6 reduced, 8 exited
  • 59 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

AI Rebalance Analysis

1. Overall Direction and Market View: The BAKER BROS. ADVISORS LP fund appears to maintain a cautious stance, with a focus on Health Care sector, suggesting a belief in the stability and growth potential of this sector. 2. Key Moves: - Added: Revolution Medicines Inc. (RVMD) and Insmed Inc. (INSM), with significant increases in share count. - Reduced: None explicitly noted, but the slight increase in the share count of Incyte Corp. (INCY) indicates a minor addition. - Hold: The majority of holdings were held steady, with no significant changes in share count or position action. 3. Portfolio Structure: - Passive/Active: The fund seems to be active, as it added new positions and increased existing ones. - Sector Bias: Strong bias towards the Health Care sector, with 83% of the total value allocated to it. - Risk Appetite: The risk appetite is moderate, with a focus on established companies in the Health Care sector and no significant reduction in positions. 4. Per-Holding One-Liner: - INCY: Biotechnology company focused on developing therapies for immune-mediated diseases. - ONC: Biopharmaceutical company specializing in the development of treatments for various diseases. - RVMD: Biotechnology company focused on developing novel therapies for cancer and other diseases. - MDGL: Biotechnology company focused on the development of therapies for rare genetic diseases. - ACAD: Biotechnology company focused on developing treatments for neurological disorders. - KYMR: Biotechnology company focused on developing treatments for cancer and other diseases. - INSM: Biotechnology company focused on the development of therapies for rare genetic diseases. - KOD: Biotechnology company focused on the development of therapies for rare genetic diseases. - RYTM: Biotechnology company focused on the development of therapies for neurological disorders. - PRAX: Biotechnology company focused on the development of therapies for various diseases. 5. One-Sentence Style Summary: BAKER BROS. ADVISORS LP maintained a conservative approach, focusing on Health Care sector with a few strategic additions, reflecting a belief in the sector's stability and growth prospects.

Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice.

Sector Allocation

Health Care 99.0%
Other 1.0%
Sort by: Value Shares Weight Sector Change · CSV
# Shares Value Weight Allocation Change
1 30.74M $3.04B 18.64%
Form 4 · 1 →
18.64%
Hold
2 8.80M $2.67B 16.41%
Form 4 · 1 →
16.41%
Hold
3 2.14M $1.25B 7.66%
Form 4 · 5 →
7.66%
Hold
4 6.59M $1.15B 7.04%
7.04%
Reduce
5 42.90M $1.15B 7.03%
7.03%
Hold
6 9.46M $753.12M 4.62%
4.62%
Hold
7 8.66M $673.62M 4.13%
4.13%
Add
8 36.39M $636.48M 3.91%
3.91%
Add
9 5.60M $599.90M 3.68%
3.68%
Hold
10 19.92M $556.94M 3.42%
Form 4 · 86 →
3.42%
Add
11 1.13M $332.02M 2.04%
2.04%
Add
12 10.01M $280.14M 1.72%
1.72%
Add
13 2.09M $178.48M 1.10%
1.10%
Add
14 6.58M $163.18M 1.00%
1.00%
Reduce
15 2.18M $144.44M 0.89%
0.89%
Add
16 1.79M $141.75M 0.87%
0.87%
Add
17 5.46M $138.74M 0.85%
0.85%
Hold
18 12.09M $126.99M 0.78%
0.78%
Hold
19 3.62M $125.10M 0.77%
0.77%
Add
20 5.56M $120.54M 0.74%
0.74%
Add
21 875.80K $118.11M 0.72%
0.72%
Hold
22 2.83M $116.58M 0.72%
0.72%
Hold
23 11.05M $107.36M 0.66%
0.66%
Hold
24 3.34M $105.91M 0.65%
0.65%
Reduce
25 1.43M $99.63M 0.61%
0.61%
Reduce
26 27.53M $94.14M 0.58%
0.58%
Hold
27 4.66M $88.37M 0.54%
0.54%
Add
28 2.32M $80.62M 0.49%
0.49%
Hold
29 10.89M $77.07M 0.47%
0.47%
Hold
30 1.65M $76.75M 0.47%
0.47%
Add
31 4.35M $68.14M 0.42%
0.42%
Reduce
32 30.75M $66.58M 0.41%
0.41%
Hold
33 2.77M $63.77M 0.39%
0.39%
Hold
34 3.73M $61.61M 0.38%
0.38%
Hold
35 1.97M $61.36M 0.38%
0.38%
Add
36 5.07M $52.15M 0.32%
0.32%
Add
37 1.55M $46.94M 0.29%
0.29%
Hold
38 950.00K $38.38M 0.24%
0.24%
New
39 368.92K $35.12M 0.22%
0.22%
Hold
40 1.00M $32.76M 0.20%
0.20%
Hold
41 789.76K $32.55M 0.20%
0.20%
Hold
42 10.12M $29.36M 0.18%
0.18%
Hold
43 1.46M $28.02M 0.17%
0.17%
Hold
44 337.05K $26.77M 0.16%
0.16%
Hold
45 1.64M $25.32M 0.15%
0.15%
New
46 4.00M $22.03M 0.14%
0.14%
Hold
47 2.82M $22.02M 0.14%
0.14%
New
48 2.35M $21.21M 0.13%
0.13%
Add
49 25.17K $21.17M 0.13%
0.13%
Reduce
50 2.23M $20.95M 0.13%
0.13%
Add

FAQ

What did BAKER BROS. ADVISORS LP buy in 2025-Q4?

In its 2025-Q4 13F filing, BAKER BROS. ADVISORS LP reported 85 equity positions worth $16.29B in aggregate; its largest disclosed positions were INCY ($3.04B), ONC ($2.67B), MDGL ($1.25B).

How large is BAKER BROS. ADVISORS LP's portfolio?

BAKER BROS. ADVISORS LP reported $16.29B of long equity holdings across 85 positions as of 2025-Q4. Top-10 holdings account for 76.6% of reported value.

What is BAKER BROS. ADVISORS LP's investment style?

HoldingsHub classifies the portfolio as Large / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/baker-bros-advisors/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →